GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » EV-to-FCF

ABVC (ABVC BioPharma) EV-to-FCF : -4.63 (As of Dec. 16, 2024)


View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, ABVC BioPharma's Enterprise Value is $8.30 Mil. ABVC BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.79 Mil. Therefore, ABVC BioPharma's EV-to-FCF for today is -4.63.

The historical rank and industry rank for ABVC BioPharma's EV-to-FCF or its related term are showing as below:

ABVC' s EV-to-FCF Range Over the Past 10 Years
Min: -2448.64   Med: -21.57   Max: 499664.33
Current: -4.63

During the past 13 years, the highest EV-to-FCF of ABVC BioPharma was 499664.33. The lowest was -2448.64. And the median was -21.57.

ABVC's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs ABVC: -4.63

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-16), ABVC BioPharma's stock price is $0.505. ABVC BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.903. Therefore, ABVC BioPharma's PE Ratio (TTM) for today is At Loss.


ABVC BioPharma EV-to-FCF Historical Data

The historical data trend for ABVC BioPharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma EV-to-FCF Chart

ABVC BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.57 -27.60 -12.51 -3.13 -2.60

ABVC BioPharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.85 -2.60 -4.98 -3.33 -5.53

Competitive Comparison of ABVC BioPharma's EV-to-FCF

For the Biotechnology subindustry, ABVC BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ABVC BioPharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's EV-to-FCF falls into.



ABVC BioPharma EV-to-FCF Calculation

ABVC BioPharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=8.301/-1.794
=-4.63

ABVC BioPharma's current Enterprise Value is $8.30 Mil.
ABVC BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.79 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ABVC BioPharma  (NAS:ABVC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

ABVC BioPharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.505/-0.903
=At Loss

ABVC BioPharma's share price for today is $0.505.
ABVC BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.903.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


ABVC BioPharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


ABVC BioPharma Business Description

Traded in Other Exchanges
N/A
Address
44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Executives
Shuling Jiang director, 10 percent owner 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng director 5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira director 4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto director 4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao director NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang director, officer: CSO and Director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang director, officer: Chairman of the Board & CBO 1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang director 1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou director 13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King officer: Chief Scientific Officer 11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong officer: Chief Executive Officer 44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An officer: Chief Financial Officer 32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang director 1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar director, 10 percent owner, officer: President,Secretary,Treasurer 8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz officer: CFO & Controller 2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326